ArticleBMJ open2023
Association between triglyceride glucose-related markers and the risk of metabolic-associated fatty liver disease: a cross-sectional study in healthy Chinese participants.
Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Triglyceride glucose waist circumference and non alcoholic fatty liver disease: a systematic review and meta analysis.BMC gastroenterology · 2025Pooled it
- The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.Hepatology international · 2025Guideline
- Pooled it
- Obstructive sleep apnea mediates the association between body mass index and metabolic dysfunction-associated steatotic liver disease in patients with obesity.Hepatology international · 2026Article
- Mechanisms of postpartum metabolic dysfunction-associated steatotic liver disease in women with a history of gestational diabetes mellitus.Endocrine connections · 2026Review
- Clinical Utility of the Triglyceride-Glucose Index in Assessing Hepatic Steatosis Severity Within the MASLD Spectrum.Diagnostics (Basel, Switzerland) · 2026Article
- Comparing the diagnostic performance of metabolic indices in metabolic dysfunction-associated fatty liver disease patients: a retrospective cross-sectional study.European journal of medical research · 2026Article
- Machine Learning Models to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With Simple Anthropometric and Biochemical Variables: A Cross-Sectional Study in US Population.International journal of hepatology · 2026Article
- The development and evaluation of nine non-conventional lipid parameters for metabolic dysfunction-associated fatty liver disease in Chinese medical health examination adults: a single-center retrospective study.Frontiers in nutrition · 2026Article
- Association between triglyceride glucose-body mass index and MASH, cardiovascular disease in MASLD patients: a cross-sectional study and machine learning analysis.Metabolism open · 2025Article
- Ability of triglyceride-glucose indices to predict metabolic dysfunction associated with steatotic liver disease in pediatric obesity.Journal of pediatric gastroenterology and nutrition · 2025Article
- The additive effect of cardiopulmonary fitness and triglyceride-glucose index on the risk of metabolic syndrome.BMC cardiovascular disorders · 2025Article
- Relationship between triglyceride and glucose related indexes and MAFLD in rural populations of northwest China.Scientific reports · 2025Article
- TyG-BMI as a superior predictor of MAFLD and pre-MAFLD in Chinese adults: a cross-sectional study.BMC gastroenterology · 2025Article
- Predictive value of the triglyceride-glucose index for coronary artery bypass grafting-acute kidney injury patients.BMC cardiovascular disorders · 2025Article
- Correlation analysis of the triglyceride-glucose index and related parameters in metabolic dysfunction-associated fatty liver disease.Scientific reports · 2025Article
- Predicting the risk of metabolic-associated fatty liver disease in the elderly population in China: construction and evaluation of interpretable machine learning models.Frontiers in medicine · 2025Article
- Relationship between TyG-related index and hearing loss in people over 45 s in China.Frontiers in public health · 2025Article
- Article
- The potential of insulin resistance indices to predict non-alcoholic fatty liver disease in patients with type 2 diabetes.BMC endocrine disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the performance of the triglyceride glucose (TyG) index and its related markers in predicting metabolic-associated fatty liver disease (MAFLD) in healthy Chinese participants.
designThis was a cross-sectional study.
settingThe study was conducted at Health Management Department of the Affiliated Hospital of Xuzhou Medical University.
participantsA total of 20 922 asymptomatic Chinese participants (56% men) were enrolled. OUTCOME MEASURES: Hepatic ultrasonography was performed to diagnose MAFLD based on the latest diagnostic criteria. The TyG, TyG-body mass (TyG-BMI) and TyG-waist circumference indices were calculated and analysed.
resultsCompared with the lowest quartile of the TyG-BMI, the adjusted ORs and 95% CIs for MAFLD were 20.76 (14.54 to 29.65), 92.33 (64.61 to 131.95) and 380.87 (263.25 to 551.05) in the second, third and fourth quartiles, respectively. According to the subgroup analysis, the TyG-BMI in the female and the lean groups (BMI<23 kg/m
conclusionsThe TyG-BMI is an effective, simple and promising tool for predicting MAFLD, especially in lean and female participants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.